Beskrivning

Lagevrio – Oral Antiviral for COVID-19 (Rx)

Lagevrio (molnupiravir) is an oral antiviral medication used for the treatment of mild to moderate COVID-19 in adults who are at high risk of progressing to severe disease. It is a nucleoside analog antiviral that works by introducing errors into the viral RNA during replication, a process known as viral “error catastrophe”, which reduces the ability of the virus to multiply.

buy Lagevrio without prescription

We sell over-the-counter Lagevrio medicine; buy medicines with no prescription
snabb, diskret och pålitlig leverans
snabb och säker betalning
handla diskret utan spår

It is not intended for hospitalized patients requiring oxygen support and is most effective when started early in the course of infection.

Nyckelfakta

• Active Ingredient: Molnupiravir
• Brand Name: Lagevrio
• Drug Class: Antiviral (ribonucleoside analog)
• Indication: Mild–moderate COVID-19 in high-risk adults
• Mechanism of Action: Induces viral RNA replication errors → inhibits SARS-CoV-2 replication
• Route: Oral capsule
• Receptstatus: Receptbelagt läkemedel

Specifikationer

• Dosage Form: Capsules
• Common Strength: 200 mg capsules
• Standard Dose: 800 mg (4 capsules) twice daily
• Treatment Duration: 5 days
• Administration: Oral, with or without food
• Onset of Action: Works during early viral replication phase
• Metabolism: Hydrolyzed to active form (N-hydroxycytidine)
• Excretion: Primarily renal
• Förvaring: Rumstemperatur

Dosering och administrering

• Take 4 capsules twice daily for 5 days
• Must be started as soon as possible after diagnosis and within early symptom onset (typically within 5 days)
• Complete the full course even if symptoms improve
• Capsules should be swallowed whole

Kompatibilitet / Lämplig användning

• Adults with mild to moderate COVID-19
• Patients at high risk of progression (e.g., older age, chronic disease, immunocompromised)
• Outpatient or early-stage treatment setting
• Not used as a substitute for vaccination

Adverse Effects

• Common: Diarrhea, nausea, dizziness, headache
• Rare: Allergic reactions
• Generally considered well tolerated in short-course use

Why Choose Lagevrio?

Lagevrio provides a simple oral 5-day antiviral regimen for early treatment of COVID-19 in high-risk patients. Its mechanism targets viral replication directly, helping reduce the risk of severe disease when used promptly after symptom onset.